Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Urges CMS To Leave MCIT In Place

Executive Summary

In a letter to CMS Administrator Chiquita Brooks-LaSure, the industry association argues that repealing MCIT would deny many Americans access to “transformational” medical technologies.

You may also be interested in...



It’s Official: CMS Repeals MCIT Rule, Leaves Door Open For Alternatives

Despite industry efforts to save what it viewed as a boon to breakthrough medical technology, US Medicare has repealed the Medical Coverage for Innovative Technologies (MCIT) rule. In a more favorable move for industry, the agency scrapped a controversial qualifying definition for coverage eligibility.

CMS Should Create New Roadmap For Breakthrough Technologies, Trade Group Urges

The Medical Device Manufacturers Association wants the US Medicare agency to come up with a new rule for implementing a coverage pathway for breakthrough devices by June 2022.

Real-World Evidence Deemed Essential For Breakthrough Designations

A panel of experts in the health care and medical device industries discussed the fate of the Medicare Coverage for Innovative Technology (MCIT) rule during AdvaMed’s annual Medtech Conference.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel